Kornimate/medical-research-clean huggingface dataset:
jaktinib and azacitidine in treating patients with mds with mf or mds/mpn with mf.

Conditions: Myelodysplastic Syndromes; Myeloproliferative Neoplasms; Myelofibrosis

Summary: this phase i/ii trial studies how well jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. giving jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.


Eligibility criteria:
inclusion criteria: * subjects voluntarily sign the informed consent form (icf); * age ≥ 18 years, either male or female; * eastern cooperative oncology group (ecog) performance status 0-2; * expected life expectancy is greater than 24 weeks; * diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm (mds/mpn) according to world health organization (who)； * the patients understands the purpose of and procedures required for the study and is willing to participate in the study； exclusion criteria: * subjects with congestive heart failure, uncontrolled or unstable angina or myocardial infarction,cerebrovascular accident, or pulmonary embolism within 6 months prior to screening; * subjects suffering from arrhythmia and requiring treatment, or qtcb \> 480ms at screening; * subjects with clinical symptoms of active bacterial, viral, parasitic or fungal infections requiring treatment at screening; * subjects with known human immunodeficiency virus (hiv), known active infectious hepatitis b (hepb), and/or known active infectious hepatitis c (hepc); * female subjects who are pregnant, currently breastfeeding, planning to become pregnant; * subjects who had experienced malignant tumors (except for adequately treated local basal cell or squamous cell carcinoma of the skin and cervical carcinoma in situ that have been cured) within the past 5 years; * subjects who have any other conditions that are not specified in the protocol but the investigator believes that they are not suitable for inclusion in this trial.

Keywords: mds mf mpn
a randomized, open-label, crossover, multicenter, single dose comparator study evaluating onset of penile rigidity in men with erectile dysfunction who are treated with sildenafil and tadalafil

Conditions: Erectile Dysfunction

Summary: the objective of this study was to determine and compare the minimum time required to achieve penile rigidity greater than or equal to 60% at the base of the penis that is sustained for at least 3 minutes measured by rigiscan®, following visual sexual stimulation post dose of 100 mg sildenafil citrate and 20 mg tadalafil in men with erectile dysfunction (ed).


Eligibility criteria:
inclusion criteria: * included subjects were 18 years of age or older * a clinical diagnosis of erectile dysfunction * known responders to either 100 mg sildenafil or 20 mg tadalafil. exclusion criteria: * excluded were subjects who were unable to achieve penile rigidity of greater than or equal to 20% at the base of the penis that was sustained for at least 3 minutes * subjects who are able to achieve penile rigidity of greater than or equal to 60% at the base of the penis that was sustained for for at least 2 minutes or subjects who are able to achieve penile rigidity of greater than or equal to 80% at the base of the penis that is sustained for for at least 1 minute measured by rigiscan®, at screening with no therapy, within 60 minutes following visual sexual stimulation * subjects currently using any commercially available treatments for erectile dysfunction * subjects on nitrates.
individualized health management of epithelial ovarian cancer: a retrospective study

Conditions: Epithelial Ovarian Cancer

Summary: the purpose of this study is to identify the demographic and sociological characteristics of epithelial ovarian cancer in a cohort, identify the risk factors of epithelial ovarian cancer, effectively identify the high-risk population of epithelial ovarian cancer in the population, implement standardized health management, and clarify the effect of standardized health management on the incidence and prognosis of epithelial ovarian cancer. it can also provide a case control population for the clinical cohort of epithelial ovarian cancer to benefit the majority of postoperative patients.

1. the clinical characteristics, preoperative hematological parameters of patients with epithelial ovarian cancer and patients with benign gynecological diseases, and the pathological stage, grade and features extracted by pet/ct images of patients with epithelial ovarian cancer were recorded. 2. patients from renji hospital were divided into training group and test group at a ratio of 7:3, and patients from shanghai first maternity and infant hospital were used as external validation group. 3. the training group was used to establish the diagnosis and prognosis prediction model of epithelial ovarian cancer, and the test group and the external validation group were used to verify the model, and the area under the roc curve, accuracy, specificity, and sensitivity were used to evaluate the effect of the model. 4. for machine learning models, shap and lime algorithms were used for model interpretation. 5. unsupervised clustering algorithm was used to distinguish the subgroups of epithelial ovarian cancer patients, and km was used to analyze the overall survival (os) and progression-free survival (pfs) to predict the survival and recurrence of the subgroups. overall survival (os) was defined as the time from the first diagnosis of epithelial ovarian cancer to the confirmation of death or the end of follow-up. progression-free survival (pfs) was defined as the time from the first diagnosis of epithelial ovarian cancer to the confirmation of disease progression or the end of follow-up.

Eligibility criteria:
inclusion criteria: * patients were diagnosed as primary epithelial ovarian cancer with definite pathological stage and grade and underwent preoperative pet/ct examination, or patients diagnosed as benign gynecological diseases including ovarian cysts, uterine fibroids, and uterine prolapse. * age between 18 to 80 years old; * complete preoperative blood routine test results, blood biochemical indicators, and tumor markers; exclusion criteria: * complicated with acute or chronic genital tract infectious diseases; * patients with diagnosed tumors other than ovarian cancer; * complicated with severe systemic diseases; * pregnant or lactating women; * patients diagnosed with recurrent epithelial ovarian cancer.

Keywords: epithelial ovarian cancer diagnosis prognosis
assessment of pain using a pain diagnostic system that measurs facial movement using

Conditions: Nursing; Pain Assessment; Critical Care; Technology; Facial Recognition

Summary: pain is a subjectively difficult, abstract and comprehensive concept that is at the core of the whole study, emerging in relation to various advancements, and detailed description. for non-controlling, stress-free, stress-or-thickness training for thromboembolic, pulmonary and other organ modalities, re-admission from discharge, thromboembolic, pulmonary and other reasons. the scales of use in the assessment of pain in the conscious surgical patient who cannot communicate verbally, into the pain, are physically subjective. ekman and friesen are planning the movements of their muscles to be performed by an action coding process that could be experienced in 1978. system; it has been applied in pain, in the evaluation of pain in the postoperative period and in children, in the new clinical practice, and in the new and clinical practice. health professionals may be biased in diagnosing pain, especially in intensive care patients, and may underestimate pain. in the literature, it is seen that the child who is made with pain in his patients in education in the field of medicine is not used in his experiences, similar to the pain that measures the tastes of the faces of the single scales. in this context, standardized, continuous, objective and scalable pain measures indicate the practice environment. the aim of these people is to evaluate the pain in our surgical patients who cannot communicate clearly and clearly with pain diagnosis that measures facial movement.


Eligibility criteria:
inclusion criteria: * 18 years and over, * those with intubation/tracheostomy, * conscious, unable to communicate verbally, * glaskow coma score 13-15, * patients who agreed to participate in the study exclusion criteria: * those with any facial abnormality that may alter facial expression analysis (facial paralysis, poland-mobius syndrome) * those with neurological and mental disorders, * having a history of chronic pain, * those who have a condition that requires them to be in the prone position all the time (pilonidal sinus, ards, etc.), * patients who cannot speak the same language as the healthcare professional

Keywords: nurse pain assessment intensive care facial diagnosis technology
dna repair activity in the skin of day and night shift workers

Conditions: Skin Cancer

Summary: the purpose of this study is to test how the skin of night shift workers responds to artificial sunlight (ultraviolet b radiation; uvb) at two different times of the day in comparison to normal day shift workers. after the skin biopsies are obtained, they will be brought to the laboratory to be exposed to uvb radiation and to measure uvb responses.


Eligibility criteria:
inclusion criteria: * male/female * fair skin (fitzpatrick types i and ii) * age 18 to 40 * able to comprehend procedures/risks * primarily work and are awake during normal daylight hours (6 am to 6 pm), or primarily work and are awake during night shifts hours (between the hours of 6 pm and 6 am) or may work a mixture of these shifts over the past 3 months. rotating shifts will be categorized based on the majority of hours worked on average during the last 3 months. able to fill out a 3-month calendar of work schedule. exclusion criteria: * known photosensitivity * currently on photosensitizing medications * diabetes mellitus * on any hormonal agents (e.g., birth control pills) * history of abnormal scarring * history of skin infections * history of skin cancers * history of sleep disorders such as sleep apnea or insomnia * known allergy to lidocaine local anesthetic * pregnancy or nursing * other serious health issues
autologous prp infusion may restore ovarian function and may promote folliculogenesis in poi patients

Conditions: Menopause, Premature; Menopause Related Conditions; Menopausal Syndrome; Premature Ovarian Failure; Ovarian Failure, Premature

Summary: autologous prp intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with poi.

this triple-blind randomized controlled trial (rct) aims to investigate the effectiveness of autologous prp intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to patients presenting with poi. prp is blood plasma prepared from fresh whole blood that has been enriched with platelets. it is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (vegf), epidermal growth factor (egf), platelet derived growth factor (pdgf), transforming growth factor (tgf) and other cytokines all of which stimulate tissue proliferation and growth. prp has been employed in several medical conditions in orthopedics, dermatology, and ophthalmology for wound healing. it's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. this study aims to investigate the effect of autologous prp intra ovarian infusion on restoring ovarian tissue functionality in poi patients.

Eligibility criteria:
inclusion criteria: * age \ 25 iu/l recorded on two occasions \>4 weeks apart * normal karyotype: 46, xx * discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment. * willing to comply with study requirements exclusion criteria: * any pathological disorder related to reproductive system anatomy * amh \> 8 pmol/l * endometriosis * adenomyosis * fibroids and adhesions * infections in reproductive system * current or previous diagnosis of cancer in reproductive system * history of familiar cancer in reproductive system * severe male factor infertility * prior referral for pgt * ovarian inaccessibility * endocrinological disorders (hypothalamus-pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * bmi\>30 kg/m2 or bmi\<18.5 kg/m2 * systematic autoimmune disorders
rhenium re 188 p2045 in patients with lung cancer who have received or refused to receive prior chemotherapy

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Neoplasm Recurrence, Local

Summary: the purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug rhenium re 188 p2045. this will be done by first treating patients at relatively low doses of rhenium re 188 p2045, observing them closely to assure that there are no bad side effects, then increasing the dose when we are confident that it is safe to do so.

we want to learn more about the side effect profile of both technetium tc 99m p2045 and rhenium re 188 p2045 and will do that by observing you closely after you receive the drug and by conducting multiple tests, as well as by asking you how you feel. we want to also learn if there is any benefit, in terms of lung cancer tumor reduction, as a result of treatment with rhenium re 188 p2045. this study has previously been posted by berlex, inc. andarix pharmaceuticals is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * has histologically or cytologically documented non-small-cell lung cancer (nsclc) or small-cell lung cancer (sclc) and has advanced or recurrent iiib or iv nsclc (adenocarcinoma, squamous cell carcinoma, large cell, mixed or not otherwise specified) or disseminated or recurrent sclc or any lung cancer which has local recurrence. * has documentation of progressive disease following prior chemotherapy or who refused to receive standard chemotherapy. * has measurable tumor (at least 1 cm unidimensionally) in a previously non-irradiated area or, if in previously irradiated area, a substantial increase in size of tumor, based on ct scan within 8 weeks prior to enrollment; tumor in previously irradiated area only if it has increased by 50% or more from previous minimal diameter and it is more than 8 weeks from the radiation.

Keywords: advanced or recurrent stage iiib or iv non small cell lung cancer disseminated or recurrent small cell lung cancer
a registry to evaluate patterns of care associated with the use of corus cad (or asges) in primary care settings

Conditions: Chest Pain; Coronary Artery Disease; Cardiovascular Diseases; Coronary Heart Disease; Angina Pectoris; CAD; CVD; CHD

Summary: the preset registry--a registry to evaluate patterns of care associated with the use of corus cad (age/sex/gene expression score - asges) in real world clinical care settings (preset)--was designed as an observational, post-market, real-world registry to evaluate patterns of care, including referrals to a cardiologist, cardiac stress testing, ct angiography, within the first month after corus cad (asges) testing.

the prospective preset registry (nct01677156) enrolled stable, nonacute adult patients presenting with typical or atypical symptoms suggestive of obstructive coronary artery disease from 21 us primary care practices from august 2012 to august 2014. demographics, clinical characteristics, and corus cad (age/sex/gene expression score - asges) results (predefined as low \[asges \ 15\]) were collected, as were referrals to cardiology or further functional/anatomic cardiac testing after corus cad (age/sex/gene expression score - asges) testing. patients were followed for 1 year post asges testing.

Eligibility criteria:
inclusion criteria: 1. symptoms suggestive of cad, according to the opinion of the site registry clinician 2. receiving corus cad (asges) to aid in the diagnosis of obstructive cad 3. age \>= 18 years 4. willing and able to provide written informed consent exclusion criteria: 1. history of myocardial infarction (mi) 2. current mi or acute coronary syndrome 3. current new york heart association (nyha) class iii or iv congestive heart failure symptoms 4. known/documented cad 5. diabetes mellitus

Keywords: asges corus cad age/sex/gene expression score gene expression ges cad cvd chd precision medicine clinical utility registry coronary artery disease angina pectoris chest pain cardiovascular disease coronary heart disease preset
a combination of coenzyme q10, feverfew and magnesium for migraine prophylaxis : a prospective observational study

Conditions: Migraine

Summary: adult patients suffering from migraine according to the criteria of the international headache society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme q10 and 112.5 mg magnesium per day for 3 months.

three visits were planned: v1, v2 on day 30 (± 10) and v3 on day 120 (± 10). on v1, after checking the inclusion criteria and receiving informed consent, gps collected demographic data, medical and migraine history and information on migraine attacks, associated symptoms and rescue medications via an electronic case report form. v1 was followed by a one-month observation period (baseline phase) during which migraine treatment of patients was not modified. from v1 till the end of the study, all patients kept an electronic diary in which they reported migraine characteristics (number of days with migraine headache, intensity, associated symptoms and concomitant medications). on the second visit (v2; day 30 ± 10), eligibility of patients was verified: patients with less than 2 or more than 15 migraine attacks during baseline phase and patients unwilling to be supplemented with the combination were excluded from the study. eligible patients were advised to start supplementation. on v3 (day 120 ± 10), information provided in patient's diary and compliance with supplementation were checked. the day before v2 and v3, patients had to complete the french migraine-related quality of life questionnaire (qualité de vie et migraine \[qvm\]) and the hospital anxiety and depression scale (hads). the study was conducted in accordance with articles l.1121-1 and r1121-2 of the french public health code defining non interventional studies; all the acts were practised and products used in a usual way without any additional or unusual procedure of diagnosis or surveillance.

Eligibility criteria:
inclusion criteria: * to suffer from migraine with or without aura diagnosed according to the criteria of the international classification of headaches disorders iii (ichd iii 1.1 and 1.2) * to suffer from migraine for more than one year * to be less than 50 years old at migraine onset * to have had at least two migraine attacks during the month before recruitment exclusion criteria: * migraine with aura with motor symptoms (hemiplegic migraine) * more than 15 migraine attacks per month * abuse of painkillers defined as the use of paracetamol, aspirin and non-steroid anti-inflammatory drugs for more than 15 days per month over the last three months or the use of triptans, opioids and ergot-type medications for more than 10 days per month during the last three months * prophylactic treatment taken for less than 3 months
anti-microbial role of non-antibiotic agents against cutibacterium acnes in patients with acne vulgaris

Conditions: Acne Vulgaris

Summary: * to evaluate and compare the anti-biofilm activity of salicylic acid, isotretinoin, and n-acetylcysteine against c. acne . * to assess the possible role of salicylic acid, isotretinoin, and n-acetylcysteine in improving the susceptibility of c. acne for azithromycin and doxycycline.

the study was carried out on 24 patients with acne vulgaris. they were recruited from the outpatient clinic of the dermatology and venereology and andrology department, zagazig university hospitals, egypt. the degree of severity of lesions was determined by the global acne grading system (gags) microbiological samples were collected from all patients for: 1. isolation of c. acnes 2. antibiotic susceptibility testing for c. acnes isolates aganist the most commonly used antibiotics in treatment of acne(azithromycin and doxycycline) in the presence and absence of salicylic acid, isotretinoin, and n-acetylcysteine 3. testing biofilm forming ability of c. acnes isolates in the presence and absence of salicylic acid, isotretinoin, and n-acetylcysteine

Eligibility criteria:
inclusion criteria: * adult patients. * patients of both sexes. * patients with acne vulgaris with different grades exclusion criteria: * patients received topical or oral treatment within 6 weeks prior to microbiological sampling
risk of acute kidney injury after intravenous contrast computed tomography scans

Conditions: Acute Kidney Injury; Contrast-induced Nephropathy

Summary: intravenous iodinated contrast media is commonly used to enhance diagnostic yield of computer tomography (ct) scans in clinical medicine. however, the perceived risk of contrast-induced nephropathy (cin) frequently limits its use. while cin is often self-limiting, it can cause significant morbidity by prolonging admissions and rendering an at-risk individual dialysis dependent. cin has long been observed and described in clinical studies. there is ample data on cin after administration of intraarterial contrast, but evidence is less compelling when it comes to intravenous contrast. increasing studies have called into question the actual risk of intravenous contrast media. expert panels are suggesting that the risk could have been overstated, leading to contrast being withheld when indicated. there is paucity of local data on this particular issue. more real world data on the actual incidence and risk factors of aki will be helpful to clinicians. the investigators plan to conduct a single center, retrospective study, to determine the incidence and risk factors of post contrast aki in contrast enhanced ct scans.

a single center, retrospective study will be conducted, looking into all patients who had contrast-enhanced ct scans done in a specified time period. serum creatinine at baseline and at 48-72 hours post-contrast of the participants will be compared to determine presence of post contrast aki (pc-aki). data on the participants' demographics, comorbidities, laboratory results and use of nephrotoxins will also be captured and analysed. the primary objective of this study is to determine the incidence of aki after intravenous contrast administration for contrast enhanced ct scans (cect). the secondary objective is to identify risk factors of pc-aki and possibly come up with a risk stratification system that can be utilized in clinical practice. the investigators hypothesize that there is significant risk of acute kidney injury after intravenous contrast media administration, but it lower than that in the setting of intraarterial contrast; and that risk factors of aki may include: pre existing chronic kidney disease, diabetes, hypertension, proteinuria, use of nephrotoxins, age, increased dose of contrast.

Eligibility criteria:
inclusion criteria: 1. underwent one or more ct scan in cgh in the stipulated study period 2. ct scan done as an inpatient or outpatient of cgh 3. serum creatinine available less than 6 months before scan 4. serum creatinine available within 1 week after scan exclusion criteria: 1. age 12 or below 2. dialysis dependent before scan (dialysis related charge code applied 24 months before scan) 3. baseline serum creatinine not available 4. post scan serum creatinine not available

Keywords: intravenous contrast acute kidney injury computer tomography